RT info:eu-repo/semantics/article
T1 Linfoma de Hodgkin
A1 Peñarrubia Ponce, María Jesús
A2 Ediciones Universidad de Valladolid
AB Thomas Hodgkin described Hodgkin�s lymphoma in the first half of the XIX century. The disease was still invariably lethal more than a century after his original description. Remarkable progress in the understanding of the pathophysiology of Hodgkin�s lymphoma and dramatic therapeutic developments occurred over the past fifty years. Nowadays between 85 and 95% of patients can be cured. There are four major landmarks on this successful path. First, the understanding of Reed-Stenberg�s cell biology. During the 1960s the true neoplastic character of this cell was established. During the 1990s it was confirmed that Reed-Stenberg cell originated from the Blymphocites of the germinal center. Secondly, the advent of accurate staging methods and the development of prognostic factors. From the 1970 the advent of computed tomography replaces laparotomy and lympography for staging, resulting in simpler yet more accurate staging. Recently, positron emission tomograpghy allows further refinement in staging. In 1971 the Ann Arbor staging system was developed and is still in use today. The International Progonostic Index developed in 1998 allowed further delineation of therapeutic subgroups. Thirdly, improvements in radiotherapy. The advent of mega-voltage devices and broad-field techniques designed by Kaplan open up the road to cure. And finally, multicenter cooperative randomized trials effectively favor application of polychemotherapy and combined treatment to patients with Hodgkin�s lymphoma. During the most recent years, studies aiming at improved cure rates and disease control together with diminished side effects are under way. New drugs such as Brentuximab Vedotin are promising.
SN 0210-6523
YR 2013
FD 2013
LK http://uvadoc.uva.es/handle/10324/23840
UL http://uvadoc.uva.es/handle/10324/23840
LA spa
NO Anales de la Real Academia de Medicina y Cirugía de Valladolid, 2013, N.50, pags.259-271
DS UVaDOC
RD 24-nov-2024